Shares of Eli Lilly (LLY) moved lower after Reuters reported Hims & Hers (HIMS) will begin offering a compounded version of Novo Nordisk’s (NVO) new Wegovy pill at an introductory price of $49 per month, or about $100 less than the brand name. Shares of Eli Lilly are down 4%, or $44.88, to $1,062.24 in premarket trading. Novo shares are down 6% to $44.42.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Hims & Hers to offer copy of Wegovy pill at $49 per month, Reuters reports
- Eli Lilly price target raised to $1,260 from $1,145 at Goldman Sachs
- Eli Lilly price target raised to $1,280 from $1,200 at Wells Fargo
- Eli Lilly price target raised to $1,300 from $1,200 at BMO Capital
- Eli Lilly price target raised to $1,300 from $1,150 at JPMorgan